Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Anti-aging pill tested in 1-year human trial

NCT ID NCT06592859

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking a daily capsule of nicotinamide mononucleotide (NMN) can reduce biological age in healthy adults aged 40-70. Over 240 participants will take either NMN or a placebo for one year. Researchers will measure aging using blood tests and other markers to see if NMN can truly slow the aging process.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nicotinamide mononucleotide (NMN) dietary supplement
What this could lead to
If it works, this could point toward a simple supplement to slow or reverse some signs of aging in healthy people.
What could go wrong
This is an early-stage study with only 240 participants, so results may not apply to everyone. NMN supplements are not regulated like drugs, and long-term safety is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

39 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Local residents of Quzhou or living in Quzhou for over ten years. 2. age 40-50 and 60-70 years old, no major bad habits. 3. Gender unlimited. 4. in good health and has not undergone major surgery within half a year. 5. Be able to communicate well with researchers and cooperate with the work during the study. 6. Written informed consent can be signed voluntarily. Exclusion criteria: 1. Alcoholism, heavy smoking (more than 5 packs/day, 20 cigarettes per pack), drug abuse or substance abuse. 2. Participants are conducting other clinical trials or using any research drugs or equipment for treatment within 30 days before enrollment (including but not limited to aspirin, metformin, resveratrol, vitamin C, etc.). 3. Obesity (bmi more than 30). 4. Pregnant/lactating women. 5. Disease history: A) under 60 years old: 1. any cancer (erythrocytosis, except basal cell or squamous cell skin cancer). 2. coronary artery disease/myocardial infarction/clinically significant congestive heart failure. 3. stroke/transient ischemic attack. 4. deep vein thrombosis/pulmonary embolism. 5. serum creatinine \> 1.5 mg/dl (male). 6. poor control of hypertension (although treated, there is still significant hypertension (systolic blood pressure \> 160 mmHg, or diastolic blood pressure \>100 mmHg)). 7. history of active liver disease or metabolic acidosis. 8. chronic kidney disease/hemodialysis treatment, history of severe kidney damage and/or EGFR ≤ 45ml/min/1.73m2. 9. severe autoimmunity/inflammation, such as rheumatoid arthritis, lupus, Crohn\'s disease, etc. 10. nervous system diseases such as dementia, such as Alzheimer/Parkinson\'s disease. 11. diabetes mellitus (hemoglobin \> 6.5% or fasting blood glucose \> 126 mg/dL or taking diabetes drugs or insulin treatment). 12. recent (within 3 months) cardiovascular events (myocardial infarction, coronary intervention, coronary artery bypass grafting). 13. infectious diseases such as HIV, hepatitis, tuberculosis, etc. 14. hand or lower limb disability affects normal function and life. B) older than 60 years: 1. any cancer (erythrocytosis, except basal cell or squamous cell skin cancer). 2. history of active liver disease or metabolic acidosis. 3. chronic kidney disease/hemodialysis treatment, history of severe kidney damage and/or EGFR ≤ 45ml/min/1.73m2. 4. severe autoimmunity/inflammation, such as lupus, Crohn\'s disease, etc. 5. nervous system diseases such as dementia, such as Alzheimer/Parkinson\'s disease. 6. recent (within 3 months) cardiovascular events (myocardial infarction, coronary intervention, coronary artery bypass grafting). 7. infectious diseases such as HIV, hepatitis, tuberculosis, etc. 8. hand or lower limb disability affects normal function and life. 6. Currently taking the following drugs regularly: A) chemotherapy drugs (such as tamoxifen, adriamycin, mitoxantrone, bleomycin). B) antiplatelet drugs (e.g., clopidogrel/Plavix, dipyridamole/anglionide, ticlopidine/ticlopidine, except aspirin). C) cholinesterase inhibitors for Alzheimer\'s disease (donepezil/alicept). 7. The researchers believe that the physical factors of the participants may have an adverse impact on the research process or results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • People's Hospital of Quzhou

    RECRUITING

    Quzhou, Zhejiang, 324000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.